188 filings
Page 3 of 10
8-K
co4f93ecs2rl3 km
12 Sep 17
Argos Therapeutics Reports on Interim Analysis of Phase 3 ADAPT Trial Presented at ESMO 2017 Congress
12:00am
8-K
tyxqv589 twki
5 Sep 17
Departure of Directors or Certain Officers
12:00am
S-8
vwhbsn
30 Aug 17
Registration of securities for employees
12:00am
EFFECT
p1788d
28 Aug 17
Notice of effectiveness
12:00am
CORRESP
bip6r
24 Aug 17
Correspondence with SEC
12:00am
UPLOAD
26x43gblz b1j
24 Aug 17
Letter from SEC
12:00am
8-K
q6ixt8k8tgcoq5hqu
2 Aug 17
Departure of Directors or Certain Officers
12:00am
CT ORDER
za4tb pbauer84
23 Jun 17
Confidential treatment order
12:00am
8-K
d7i4glo8k f5vozen4en
16 Jun 17
Argos Therapeutics Announces $6,000,000 Secured Convertible Note Financing
12:00am
8-K
qesaglet
4 May 17
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12:00am
10-K/A
w57fk4 he9jt2
1 May 17
Annual report (amended)
12:00am
CT ORDER
tkzp8 fcag
27 Apr 17
Confidential treatment order
12:00am
8-K
uwe1zshswj0o4w
18 Apr 17
Argos Reports Interim Results of the ADAPT Trial and Provides Perspective on Decision to Continue the Trial
12:00am
8-K
nqg r3fgacn8
14 Apr 17
Other Events
12:00am
8-K
tbmuy5
4 Apr 17
Departure of Directors or Certain Officers
12:00am